BD invests $1.2 billion in syringes

BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

One of the world’s leading medical technology companies announced plans today to invest approximately $1.2 billion over the next four years in expanding and upgrading its manufacturing capabilities and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across six manufacturing facilities worldwide and to add a new manufacturing facility in Europe.

In Europe, the new manufacturing facility is expected to be operational by the end of 2023. Additionally, the investment is expected to fund capacity expansion, new product developments, manufacturing technology enhancements, and business continuity improvements throughout its existing network, all designed to maximize supply and reduce risks for pharmaceutical companies that use ready-to-fill syringes for their injectable drugs – including complex biologics, vaccines, and small molecules.    

Follow us:

Share this article:

Share on linkedin
LinkedIn

Sign Up to our newsletter

What are they signing up yo with the newsletter?

At Easyfairs, we take your privacy seriously and will only use the information we collect or receive about you in accordance with our privacy policy. If you change your mind you can unsubscribe at any time.